Differential MyD88/IRAK4 requirements for cross-priming and tumor rejection induced by heat shock protein 70-model antigen fusion protein

Shusaku Mizukami, Chiaki Kajiwara, Masato Tanaka, Tsuneyasu Kaisho, Heiichiro Udono

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Priming of CD8 + T cells requires two signals, one produced by T-cell receptor recognition of antigen, and a second that is often provided by the innate immune response. In this context, antigens non-covalently or covalently associated with heat shock proteins (HSP) are internalized and processed in antigen-presenting cells (APC) to be presented by MHC I molecules to CD8 + T cells, thus, signal 1 has been well characterized in this pathway of cross-presentation. Signal 2 is not fully understood, although there are reports that Toll-like receptors (TLRs) interact with HSP and activate APC. The ability of HSP to activate APC through TLRs is, however, controversial because of the possibility of endotoxin contamination. Using a variety of TLR KO mice, we present evidence that TLRs (TLR2, 3, 4, 7, and 9) and their adaptor molecules MyD88 and IRAK4 are dispensable in cross-priming by a mycobacterial HSP70-antigen (ovalbumin as a model antigen) fusion protein; in contrast, MyD88/IRAK4, but not TLRs, are required for tumor rejection induced by the same reagent. Our results indicate that HSP-mediated cross-priming uses a second signal produced by mechanisms other than TLR cascades. We hypothesize that efficient cross-priming by HSP70 alone is insufficient for tumor rejection and that MyD88/IRAK4-dependent inflammatory stimulation, which might contribute to maintenance of the initially primed effector cells, is required to eradicate tumor burden.

Original languageEnglish
Pages (from-to)851-859
Number of pages9
JournalCancer Science
Volume103
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Cross-Priming
HSP70 Heat-Shock Proteins
Toll-Like Receptors
Heat-Shock Proteins
Antigens
Antigen-Presenting Cells
Neoplasms
Proteins
Toll-Like Receptor 3
T-Lymphocytes
Ovalbumin
T-Cell Antigen Receptor
Tumor Burden
Innate Immunity
Endotoxins
Maintenance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Differential MyD88/IRAK4 requirements for cross-priming and tumor rejection induced by heat shock protein 70-model antigen fusion protein. / Mizukami, Shusaku; Kajiwara, Chiaki; Tanaka, Masato; Kaisho, Tsuneyasu; Udono, Heiichiro.

In: Cancer Science, Vol. 103, No. 5, 05.2012, p. 851-859.

Research output: Contribution to journalArticle

Mizukami, Shusaku ; Kajiwara, Chiaki ; Tanaka, Masato ; Kaisho, Tsuneyasu ; Udono, Heiichiro. / Differential MyD88/IRAK4 requirements for cross-priming and tumor rejection induced by heat shock protein 70-model antigen fusion protein. In: Cancer Science. 2012 ; Vol. 103, No. 5. pp. 851-859.
@article{4da79be8f94e4d819d3a0507f14ae4a9,
title = "Differential MyD88/IRAK4 requirements for cross-priming and tumor rejection induced by heat shock protein 70-model antigen fusion protein",
abstract = "Priming of CD8 + T cells requires two signals, one produced by T-cell receptor recognition of antigen, and a second that is often provided by the innate immune response. In this context, antigens non-covalently or covalently associated with heat shock proteins (HSP) are internalized and processed in antigen-presenting cells (APC) to be presented by MHC I molecules to CD8 + T cells, thus, signal 1 has been well characterized in this pathway of cross-presentation. Signal 2 is not fully understood, although there are reports that Toll-like receptors (TLRs) interact with HSP and activate APC. The ability of HSP to activate APC through TLRs is, however, controversial because of the possibility of endotoxin contamination. Using a variety of TLR KO mice, we present evidence that TLRs (TLR2, 3, 4, 7, and 9) and their adaptor molecules MyD88 and IRAK4 are dispensable in cross-priming by a mycobacterial HSP70-antigen (ovalbumin as a model antigen) fusion protein; in contrast, MyD88/IRAK4, but not TLRs, are required for tumor rejection induced by the same reagent. Our results indicate that HSP-mediated cross-priming uses a second signal produced by mechanisms other than TLR cascades. We hypothesize that efficient cross-priming by HSP70 alone is insufficient for tumor rejection and that MyD88/IRAK4-dependent inflammatory stimulation, which might contribute to maintenance of the initially primed effector cells, is required to eradicate tumor burden.",
author = "Shusaku Mizukami and Chiaki Kajiwara and Masato Tanaka and Tsuneyasu Kaisho and Heiichiro Udono",
year = "2012",
month = "5",
doi = "10.1111/j.1349-7006.2012.02233.x",
language = "English",
volume = "103",
pages = "851--859",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Differential MyD88/IRAK4 requirements for cross-priming and tumor rejection induced by heat shock protein 70-model antigen fusion protein

AU - Mizukami, Shusaku

AU - Kajiwara, Chiaki

AU - Tanaka, Masato

AU - Kaisho, Tsuneyasu

AU - Udono, Heiichiro

PY - 2012/5

Y1 - 2012/5

N2 - Priming of CD8 + T cells requires two signals, one produced by T-cell receptor recognition of antigen, and a second that is often provided by the innate immune response. In this context, antigens non-covalently or covalently associated with heat shock proteins (HSP) are internalized and processed in antigen-presenting cells (APC) to be presented by MHC I molecules to CD8 + T cells, thus, signal 1 has been well characterized in this pathway of cross-presentation. Signal 2 is not fully understood, although there are reports that Toll-like receptors (TLRs) interact with HSP and activate APC. The ability of HSP to activate APC through TLRs is, however, controversial because of the possibility of endotoxin contamination. Using a variety of TLR KO mice, we present evidence that TLRs (TLR2, 3, 4, 7, and 9) and their adaptor molecules MyD88 and IRAK4 are dispensable in cross-priming by a mycobacterial HSP70-antigen (ovalbumin as a model antigen) fusion protein; in contrast, MyD88/IRAK4, but not TLRs, are required for tumor rejection induced by the same reagent. Our results indicate that HSP-mediated cross-priming uses a second signal produced by mechanisms other than TLR cascades. We hypothesize that efficient cross-priming by HSP70 alone is insufficient for tumor rejection and that MyD88/IRAK4-dependent inflammatory stimulation, which might contribute to maintenance of the initially primed effector cells, is required to eradicate tumor burden.

AB - Priming of CD8 + T cells requires two signals, one produced by T-cell receptor recognition of antigen, and a second that is often provided by the innate immune response. In this context, antigens non-covalently or covalently associated with heat shock proteins (HSP) are internalized and processed in antigen-presenting cells (APC) to be presented by MHC I molecules to CD8 + T cells, thus, signal 1 has been well characterized in this pathway of cross-presentation. Signal 2 is not fully understood, although there are reports that Toll-like receptors (TLRs) interact with HSP and activate APC. The ability of HSP to activate APC through TLRs is, however, controversial because of the possibility of endotoxin contamination. Using a variety of TLR KO mice, we present evidence that TLRs (TLR2, 3, 4, 7, and 9) and their adaptor molecules MyD88 and IRAK4 are dispensable in cross-priming by a mycobacterial HSP70-antigen (ovalbumin as a model antigen) fusion protein; in contrast, MyD88/IRAK4, but not TLRs, are required for tumor rejection induced by the same reagent. Our results indicate that HSP-mediated cross-priming uses a second signal produced by mechanisms other than TLR cascades. We hypothesize that efficient cross-priming by HSP70 alone is insufficient for tumor rejection and that MyD88/IRAK4-dependent inflammatory stimulation, which might contribute to maintenance of the initially primed effector cells, is required to eradicate tumor burden.

UR - http://www.scopus.com/inward/record.url?scp=84862782784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862782784&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02233.x

DO - 10.1111/j.1349-7006.2012.02233.x

M3 - Article

VL - 103

SP - 851

EP - 859

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -